| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Schizandrin targets multiple pathways involved in oxidative stress, inflammation, and apoptosis. It reduces the formation of reactive oxygen species (ROS) and preserves mitochondrial membrane potential, thereby inhibiting the mitochondrial pathway of apoptosis. Schizandrin also exhibits anti-inflammatory activity by reducing the production of pro-inflammatory cytokines and inhibiting inflammatory signaling pathways. The compound's hepatoprotective effects are mediated through the inhibition of oxidative stress and apoptosis in hepatocytes.
|
|---|---|
| ln Vitro |
In RAW 264.7 cells, schisandrin (10-100 μM; 2 h pretreatment) dose-dependently suppresses LPS-stimulated NO generation, iNOS protein, and mRNA expression [1]. In LPS-stimulated RAW 264.7 macrophages, schisandrin (25–100 μM; 2 hours pretreatment) suppresses prostaglandin E2 synthesis, COX-2 protein, and mRNA expression [1]. SK-HEP-1, SNU-638, and T47D cell proliferation is inhibited by schisandrin, with IC50 values of 42.0, 53.1, and 40.0 μM, respectively [3]. Schisandrin (10–60 μM; 48 hours) preferentially reverses MCF-7/DOX resistance and amplifies apoptosis elicited by doxorubicin [4].
In vitro, schizandrin has demonstrated antioxidant, anti-inflammatory, and cytoprotective activities. It reduces the formation of ROS and preserves mitochondrial membrane potential in isolated rat cortical cells. Schizandrin protects against glutamate-induced neurotoxicity, suggesting potential benefits in neurodegenerative diseases. The compound also exhibits anti-cancer activity by inhibiting cancer cell proliferation and inducing apoptosis. |
| ln Vivo |
In mice, schisandrin (10–100 mg/kg; single intraperitoneal injection) decreases paw edema brought on by carrageenan and prevents peritoneal vascular permeability brought on by acetic acid [1]. Schisandrin (1–10 mg/kg; single oral dosage) dramatically improves oxotremorine-induced tremor in rats and overcomes scopolamine-induced deficits in spatial memory and passive avoidance responses [2].
In vivo, schizandrin has demonstrated hepatoprotective, antioxidant, anti-inflammatory, and anti-cancer effects in animal models. The compound protects against liver injury induced by various toxins and reduces oxidative stress and inflammation in the liver. Schizandrin has also been shown to have neuroprotective effects, protecting against glutamate-induced neurotoxicity. These in vivo studies support the traditional use of *Schisandra chinensis* for liver and nervous system health. |
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) assays for schizandrin are not extensively documented. However, the compound's antioxidant activity can be assessed using cell-free assays such as DPPH radical scavenging or ABTS assays. The compound's ability to inhibit lipid peroxidation can also be measured. Additionally, the compound's binding affinity for the adiponectin receptor 2 (AdipoR2) has been reported, and radioligand binding assays could be used to characterize this interaction.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: RAW 264.7 Macrophage Tested Concentrations: 12.5, 25, 50, 100 μM Incubation Duration: Pretreatment for 2 hrs (hours), then incubated with LPS (1 μg/mL) for 18 hrs (hours) Experimental Results: iNOS protein expression demonstrated significant in a dose-dependent manner. Dramatically inhibits COX-2 protein expression. In vitro cellular assays for schizandrin are performed using various cell types, including neurons, hepatocytes, and cancer cells. Cells are treated with schizandrin and exposed to oxidative stress, inflammatory stimuli, or neurotoxic agents. Reactive oxygen species production is measured using fluorescent dyes. Cell viability and apoptosis are assessed using MTT assays and flow cytometry. Inflammatory cytokine expression is measured by ELISA or quantitative PCR. These assays confirm the antioxidant, cytoprotective, and anti-inflammatory activities of schizandrin. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice (4 weeks) were intraperitoneally (ip) (ip) injected with λ-carrageenan [1] in the right hind paw.
Doses: 100, 200 mg/kg. Route of Administration: single ip. Experimental Results: Inhibited paw edema by 33.43% (100 mg /kg) and 57.38 % (200 mg/kg) at 3 hrs (hrs (hours)). In vivo animal experiments for schizandrin are conducted in models of liver injury, neurotoxicity, and cancer. Mice or rats are administered schizandrin via oral or intraperitoneal injection, and disease progression is monitored. Endpoints include serum markers of liver function, oxidative stress markers, inflammatory cytokine levels, and histopathological assessment of tissue damage. The compound's neuroprotective effects are evaluated in models of glutamate-induced neurotoxicity or other neurodegenerative conditions. |
| ADME/Pharmacokinetics |
Schizandrin has a molecular weight of 432.51 g/mol and a molecular formula of C24H32O7. Detailed pharmacokinetic properties such as bioavailability, half-life, and tissue distribution have not been extensively reported in the available literature. As a lignan, schizandrin may have moderate oral bioavailability and may undergo extensive metabolism. Further pharmacokinetic studies would be necessary to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Schizandrin has been evaluated in preclinical studies and has been reported to be well-tolerated at effective doses. No significant toxicity has been reported in the available literature. As a natural product with a long history of use in traditional medicine, schizandrin is generally considered to have a favorable safety profile. However, comprehensive toxicology studies would be necessary to fully assess its safety for clinical development.
|
| References | |
| Additional Infomation |
Schisantherin has been reported to be present in Schisandra chinensis, Schisandra chinensis, and other organisms with relevant data. See also: Schisandra chinensis fruit (partial).
Schizandrin is a dibenzocyclooctadiene lignan isolated from *Schisandra chinensis* Baill. It exhibits antioxidant, hepatoprotective, anti-cancer, and anti-inflammatory activities. Schizandrin reduces ROS formation, inhibits the mitochondrial pathway of apoptosis, and protects against glutamate-induced neurotoxicity. It is a major component of *S. chinensis* and has diverse biological activities. Schizandrin is a research compound with potential applications in liver diseases, neurodegenerative disorders, and cancer. |
| Molecular Formula |
C24H32O7
|
|---|---|
| Molecular Weight |
432.51
|
| Exact Mass |
432.214
|
| CAS # |
7432-28-2
|
| Related CAS # |
Schisandrin B;61281-37-6;Schisandrin C;61301-33-5;Schisandrin A;61281-38-7
|
| PubChem CID |
3001664
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
576.7±50.0 °C at 760 mmHg
|
| Melting Point |
128-129ºC
|
| Flash Point |
302.6±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
4.18
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
574
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O([H])[C@]1(C([H])([H])[H])C([H])([H])C2=C([H])C(=C(C(=C2C2=C(C(=C(C([H])=C2C([H])([H])[C@]1([H])C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
YEFOAORQXAOVJQ-RZFZLAGVSA-N
|
| InChi Code |
InChI=1S/C24H32O7/c1-13-9-14-10-16(26-3)20(28-5)22(30-7)18(14)19-15(12-24(13,2)25)11-17(27-4)21(29-6)23(19)31-8/h10-11,13,25H,9,12H2,1-8H3/t13-,24-/m0/s1
|
| Chemical Name |
(9S,10S)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol
|
| Synonyms |
Magnolia Vine Gomisins Schizandrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1 mg/mL (~2.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.28 mg/mL (0.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3121 mL | 11.5604 mL | 23.1209 mL | |
| 5 mM | 0.4624 mL | 2.3121 mL | 4.6242 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3121 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
